Skip to main content

Table 2 Clinicopathological features of main pancreatic duct (MPD)-involved type intraductal papillary mucinous neoplasms (IPMNs)

From: Threshold of main pancreatic duct for malignancy in intraductal papillary mucinous neoplasm at head-neck and body-tail

 

Total (n = 88)

Low-intermediate grade (n = 47)

High-grade/invasive carcinoma (n = 41)

p

Age (years)

64.52 ± 8.83

64.94 ± 8.29

64.05 ± 9.48

0.641

Size (cm)

3.88 ± 1.94

3.95 ± 2.09

3.79 ± 1.75

0.702

Sex (male/female)

55/33

27/20

28/13

0.294

Location

 Head and neck

61 (69.32%)

28 (59.57%)

33 (80.49%)

0.046

 Body and tail

26 (30.68%)

18 (40.43%)

8 (19.51%)

 

CEA (ng/ml)

4.08 ± 4.46

3.24 ± 2.22

5.03 ± 5.99

0.060

CA19-9 (U/ml)

66.93 ± 299.17

16.04 ± 25.78

126.74 ± 435.65

0.085

MPD diameter (mm)

9.03 ± 4.33

8.15 ± 4.29

10.01 ± 4.22

0.045

Mural nodule (yes)

14 (15.91%)

4 (8.51%)

10 (24.39%)

0.042

Lymph node metastasis (yes)

2 (2.27%)

0

2 (4.88%)

0.214

Extra-pancreas extension (yes)

5 (5.68%)

0

5 (12.20%)

0.019

Symptom (yes)

38 (43.18%)

17 (36.17%)

21 (52.22%)

0.155

Pancreatitis (yes)

0

0

0

Diabetes Mellitus (yes)

17 (17.29%)

4 (8.51%)

13 (31.70%)

0.006

Complications (yes)

37 (42.05%)

20 (42.55%)

17 (41.46%)

0.918

  1. CA19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen